Cédric Annweiler1, Guylaine Ferland2, Pascale Barberger-Gateau3, Antoine Brangier4, Yves Rolland5, Olivier Beauchet4. 1. Department of Neuroscience, Division of Geriatric Medicine, UPRES EA4638, UNAM, Angers University Hospital, France. Robarts Research Institute, The University of Western Ontario, London, Canada. CeAnnweiler@chu-angers.fr. 2. Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Quebec, Canada. 3. Centre INSERM U897-Epidemiologie-Biostatistique, ISPED, Université Bordeaux, France. Centre INSERM U897-Epidemiologie-Biostatistique, INSERM, ISPED, Bordeaux, France. 4. Department of Neuroscience, Division of Geriatric Medicine, UPRES EA4638, UNAM, Angers University Hospital, France. 5. Department of Geriatric Medicine, Institut du Vieillissement, University Hospital, INSERM-U1027, Toulouse, France.
Abstract
BACKGROUND: Vitamin K is involved in brain physiology, suggesting that its deficiency induces cognitive decline. Our objective was to determine whether using vitamin K antagonists (VKAs) was associated with cognitive impairment among geriatric patients. METHODS: Two hundred sixty-seven older patients (mean, 83.4 ± 8.1 years; 56.9% female) were categorized according to cognitive impairment (ie, Mini-Mental State Examination ≤ 25). The regular use of VKAs was sought by questioning the patients, relatives, and family physicians. Age, gender, body mass index, comorbidity burden, mood and executive functioning, history of atrial fibrillation, ischemic stroke, intracranial hemorrhage and transient ischemic attack, use of other anticoagulants and antiplatelet medications, and severe renal failure were used as potential confounders. RESULTS: Compared with participants without cognitive impairment (n = 70), those with Mini-Mental State Examination ≤ 25 used more frequently VKAs (p = .038). The risk of cognitive impairment was 15% higher with VKAs, specifically with fluindione. Using VKAs was independently associated with cognitive impairment (fully adjusted odds ratio = 17.4 [95% CI: 1.4-224.2], p = .028). CONCLUSIONS: We found more frequent cognitive impairment associated with the use of VKAs, specifically fluindione, among geriatric patients.
BACKGROUND:Vitamin K is involved in brain physiology, suggesting that its deficiency induces cognitive decline. Our objective was to determine whether using vitamin K antagonists (VKAs) was associated with cognitive impairment among geriatric patients. METHODS: Two hundred sixty-seven older patients (mean, 83.4 ± 8.1 years; 56.9% female) were categorized according to cognitive impairment (ie, Mini-Mental State Examination ≤ 25). The regular use of VKAs was sought by questioning the patients, relatives, and family physicians. Age, gender, body mass index, comorbidity burden, mood and executive functioning, history of atrial fibrillation, ischemic stroke, intracranial hemorrhage and transient ischemic attack, use of other anticoagulants and antiplatelet medications, and severe renal failure were used as potential confounders. RESULTS: Compared with participants without cognitive impairment (n = 70), those with Mini-Mental State Examination ≤ 25 used more frequently VKAs (p = .038). The risk of cognitive impairment was 15% higher with VKAs, specifically with fluindione. Using VKAs was independently associated with cognitive impairment (fully adjusted odds ratio = 17.4 [95% CI: 1.4-224.2], p = .028). CONCLUSIONS: We found more frequent cognitive impairment associated with the use of VKAs, specifically fluindione, among geriatric patients.
Authors: Sergey Kalinin; Natalia Marangoni; Katarzyna Kowal; Arunangsu Dey; Kinga Lis; Sergey Brodsky; Richard van Breemen; Zane Hauck; Richard Ripper; Israel Rubinstein; Guy Weinberg; Douglas L Feinstein Journal: Toxicol Sci Date: 2017-09-01 Impact factor: 4.849
Authors: Giovanni Pulignano; Donatella Del Sindaco; Maria Denitza Tinti; Stefano Tolone; Giovanni Minardi; Antonio Lax; Massimo Uguccioni Journal: Heart Int Date: 2016-09-22
Authors: Christos A Papanastasiou; Christina A Theochari; Nikos Zareifopoulos; Angelos Arfaras-Melainis; George Giannakoulas; Theodoros D Karamitsos; Leonidas Palaiodimos; George Ntaios; Konstantinos I Avgerinos; Dimitrios Kapogiannis; Damianos G Kokkinidis Journal: J Gen Intern Med Date: 2021-07-09 Impact factor: 6.473